March 26 (Reuters) - Denmark's Novo Nordisk said on Thursday it had decided to submit interim analysis data from a clinical trial of its crucial new insulin drug Tresiba to U.S. regulators within the ...
* Says Novo Nordisk submits application to the European Medicines Agency (EMA) for including data from the two SWITCH trials in the Tresiba label Sign up here. * Says during the first SWITCH study's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback